For research use only. Not for therapeutic Use.
ABBV-744 (Cat No.:I013997) is an investigational small molecule compound developed by AbbVie, a pharmaceutical company. It is a selective inhibitor of the bromodomain and extra-terminal (BET) proteins, specifically targeting bromodomain-containing protein 4 (BRD4). ABBV-744 modulates the activity of BRD4, which plays a role in regulating gene expression and cellular signaling pathways. Preclinical studies suggest that ABBV-744 may have therapeutic potential in the treatment of various cancers, including hematological malignancies and solid tumors. By inhibiting BRD4, ABBV-744 aims to disrupt oncogenic signaling, inhibit tumor growth, and potentially overcome resistance to existing therapies. However, it’s important to note that ABBV-744 is still under investigation and further clinical trials are needed to evaluate its safety and efficacy in human patients.
| Catalog Number | I013997 |
| CAS Number | 2138861-99-9 |
| Synonyms | ABBV-744; |
| Molecular Formula | C28H30FN3O4 |
| Purity | ≥95% |
| Target | BDII-selective BET bromodomain inhibitor |
| Solubility | DMSO |
| IUPAC Name | N-ethyl-4-[2-(4-fluoro-2,6-dimethylphenoxy)-5-(2-hydroxypropan-2-yl)phenyl]-6-methyl-7-oxo-1H-pyrrolo[2,3-c]pyridine-2-carboxamide |
| InChI | InChI=1S/C28H30FN3O4/c1-7-30-26(33)22-13-20-21(14-32(6)27(34)24(20)31-22)19-12-17(28(4,5)35)8-9-23(19)36-25-15(2)10-18(29)11-16(25)3/h8-14,31,35H,7H2,1-6H3,(H,30,33) |
| InChIKey | OEDSFMUSNZDJFD-UHFFFAOYSA-N |
| SMILES | CCNC(=O)C1=CC2=C(N1)C(=O)N(C=C2C3=C(C=CC(=C3)C(C)(C)O)OC4=C(C=C(C=C4C)F)C)C |
| Reference | [1]FIDANZE, Steven D., et al. BROMODOMAIN INHIBITORS. WO 2017177955 A1. |
